NutriBand Inc. (NASDAQ: NTRB)

Nutriband Inc. is a Nevada corporation that focuses on the development of transdermal pharmaceutical products. The company’s core activity revolves around its proprietary AVERSA abuse deterrent transdermal technology. This technology is designed to be incorporated into existing transdermal patches that contain drugs prone to abuse and misuse such as opioids and stimulants. By adding aversive agents to the patch backing Nutriband aims to deter oral buccal and inhalation abuse while preserving the therapeutic drug delivery. The company’s lead product candidate is AVERSA Fentanyl which combines an approved generic fentanyl patch with the AVERSA technology. Nutriband also advances AVERSA Buprenorphine and AVERSA Methylphenidate following a similar development approach. In addition to its own pipeline Nutriband pursues transdermal delivery of approved injectable biologics to improve patient compliance and therapeutic outcomes. The firm’s headquarters are located in Orlando Florida with a manufacturing affiliate in Cherryville North Carolina.

Nutriband generates revenue primarily through contract services provided by its two wholly owned subsidiaries. Pocono Pharmaceuticals operating as Active Intelligence offers contract manufacturing for health wellness and over the counter pharmaceutical customers. This includes formulation blending filling and packaging of topical and transdermal products. 4P Therapeutics provides contract research and development services for pharmaceutical and medical device clients. These services encompass early stage preclinical and clinical studies formulation analytical consulting and clinical regulatory support. The company does not yet derive significant sales from its own transdermal product candidates as they remain in development stages. Revenue from the subsidiaries helps fund ongoing research and development efforts for the AVERSA pipeline. Nutriband may also earn future milestone payments and royalties from partnership agreements such as the collaboration with Kindeva Drug Delivery for AVERSA Fentanyl.

The company operates through the following segments:

• Pocono Pharmaceuticals (operating as Active Intelligence) provides contract manufacturing services for health wellness and over the counter pharmaceutical customers. The subsidiary handles formulation development blending filling packaging and quality control of topical and transdermal products. It operates a cGMP compliant facility in Cherryville North Carolina that supports both Nutriband’s internal projects and external client orders. Pocono’s manufacturing capabilities enable the company to produce pilot batches for clinical trials and commercial scale runs for approved products.

• 4P Therapeutics delivers contract research and development services to pharmaceutical and medical device companies. Its offerings include early stage drug discovery preclinical efficacy and safety testing Phase 1 clinical trial support and formulation analytical consulting. The subsidiary also provides clinical regulatory advice and assistance with investigational new drug submissions. 4P Therapeutics maintains a small client base and uses its expertise to support Nutriband’s own pipeline development while generating fee for service revenue. The work is conducted on a project basis with no long term commitments from either party.

Nutriband occupies a niche within the transdermal drug delivery sector by specializing in abuse deterrent technologies. Its primary competitors include large pharmaceutical firms that market generic fentanyl buprenorphine and methylphenidate patches without abuse deterrent features. Specialty pharmaceutical companies that focus on novel drug delivery systems also represent competitive pressure. Nutriband’s competitive advantage lies in its patented AVERSA technology which has received patents in 46 countries and provides a proven method to deter abuse while preserving drug release characteristics. The company can leverage the 505(b)(2) regulatory pathway for its product candidates allowing reliance on existing safety and efficacy data for the active ingredient. This approach reduces clinical development requirements and may accelerate time to market compared with new chemical entities. Additionally Nutriband’s ability to partner with established contract development and manufacturing organizations such as Kindeva Drug Delivery enhances its technical and commercial capabilities.

The company serves health and wellness manufacturers that seek contract manufacturing of topical and transdermal products. Over the counter pharmaceutical firms rely on Pocono Pharmaceuticals for production of creams gels and patches. Pharmaceutical and medical device organizations engage 4P Therapeutics for outsourced research development and consulting services. Nutriband’s own future transdermal product candidates will target patients suffering from chronic pain opioid use disorder and attention deficit hyperactivity disorder as well as healthcare providers and payers. The business model emphasizes building long term relationships with clients who require reliable manufacturing or specialized R&D support.